Skip to main content

We are moving the science of heart failure forward.

Ventric Health is a medical device company focused on helping clinicians find heart failure in the primary care setting. Earlier detection of heart failure enables earlier treatment and better outcomes. Patients identified with Vivio show a 20% increase in GDMT prescription rates.1 Vivio is the only non-invasive medical device cleared by FDA to indicate the presence of elevated filling pressure (e.g. left ventricular end diastolic pressure or LVEDP).2

Graphic

Data is our DNA.

Through our academic origins, we were able to discover unprecedented scientific data on the human heart. Today, we are using that insight to develop a suite of innovations that reduces the impact of heart failure, enabling value-based care organizations and healthcare teams to lower costs and improve patient lives.

Meet Ventric Health

Cardiovascular health poses unique challenges.

Diagnostics are delayed and inefficient, and the burden on our healthcare system is growing.

50%

of patients with heart failure have symptoms overlooked during a normal clinical assessment3

65%

of at-risk patients are diagnosed in the ER or inpatient setting4-6

75%

of patients with lower socioeconomic status (SES) are diagnosed in the ER or inpatient setting4-5

30 months

can elapse between the initial onset of symptoms and a diagnosis6

$219 billion

in annual healthcare expenditures are attributed to cardiovascular diseases7

3/4

of heart failure costs are attributed to inpatient care8

Ventric Health believes the path to positively impacting cardiovascular health is through clinicians at the point of care — including the home environment.

Cardiovascular diseases are the leading cause of death in the U.S. and, despite advances in cardiovascular care, the gap in diagnosing the risk of heart disease remains. In our most vulnerable populations, symptoms are overlooked and diagnostic processes are invasive and costly — leading to poor patient outcomes.

Vivio device
Picture of Ventric device
Introducing

Vivio®

By  
Ventric Health

Vivio enables non-invasive diagnosis of at-risk patients in the primary care setting in the earliest stages of heart failure. Clinicians can perform tests in under five minutes and receive results in real time.

Vivio ® has superior sensitivity to elevated filling pressure (i.e. LVEDP)9-10. This increased sensitivity allows clinicians to identify patients earlier.

Vivio incorporates the use of the Kansas City Cardiomyopathy Questionnaire 12 (KCCQ-12). Approximately 70% of patients identified with Vivio exhibit signs and symptoms on the KCCQ-12 consistent with Stage C heart failure and 30% are consistent with Stage B heart failure11.

Wherever a patient is, clinicians can utilize Vivio’s advanced algorithms to non-invasively evaluate and detect elevated left ventricular end-diastolic pressure (LVEDP).

Graphic of medical software on a computer screen
Learn more
Request a demo
Graphic of medical person and screenshot

Resources

Resource Center
Clinical Article
Spertus et al., MedRxiv, 2025
Screening Outpatients at Risk for Heart Failure (Pre-print)

Diagnostic yield and health status of outpatients at risk for HF using Vivio and the KCCQ-12

Read more
Clinical Article
Jin, et al., Circulation, 2024
Limitations of BNP in detecting early-stage heart failure

A prospective comparison of BNP to detect elevated LVEDP as compared to invasive Millar catheter

Read more
Clinical Article
Shavelle, et al., Circulation, 2023
Multicenter validation of the Vivio System for detecting elevated left ventricular end diastolic pressure (LVEDP)

A prospective simultaneous head-to-head comparison of the Vivio vs. high-fidelity Millar catheter

Read more
95% of patients prefer the Vivio device over an echocardiogram.12
100% of patients reported the test was easy for a clinician to perform on them.12
Why Ventric Health?

Our past, present and future in cardiovascular health.